Stevanato Group/$STVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Stevanato Group
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
- Ticker
- $STVN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,010
- Headquarters
- Piombino Dese, Italy
- Website
- www.stevanatogroup.com
Stevanato Group Metrics
BasicAdvanced
$4.2B
27.47
$0.56
0.80
$0.06
0.40%
Price and volume
Market cap
$4.2B
Beta
0.8
52-week high
$24.01
52-week low
$12.05
Average daily volume
991K
Dividend rate
$0.06
Financial strength
Current ratio
1.729
Quick ratio
1.182
Long term debt to equity
0.215
Total debt to equity
0.296
Dividend payout ratio (TTM)
21.00%
Interest coverage (TTM)
41.29%
Profitability
EBITDA (TTM)
340.994
Gross margin (TTM)
29.38%
Net profit margin (TTM)
11.25%
Operating margin (TTM)
17.95%
Effective tax rate (TTM)
30.74%
Revenue per employee (TTM)
$230,240
Management effectiveness
Return on assets (TTM)
5.51%
Return on equity (TTM)
9.26%
Valuation
Price to earnings (TTM)
27.471
Price to revenue (TTM)
3.065
Price to book
2.63
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-466.039
Free cash flow yield (TTM)
-0.21%
Free cash flow per share (TTM)
-0.033
Dividend yield (TTM)
0.40%
Forward dividend yield
0.40%
Growth
Revenue change (TTM)
6.64%
Earnings per share change (TTM)
0.10%
3-year revenue growth (CAGR)
5.70%
3-year earnings per share growth (CAGR)
-3.07%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Analyst projections of the future price of Stevanato Group stock.
Bulls say / Bears say
Third-quarter revenue rose 8% and diluted earnings per share grew 15%, showing that Stevanato continued to grow sales and earnings. Its 2026 outlook also points to adjusted EBITDA of €335.0m–€345.2m. (Business Wire)
High-value solutions grew 16% in the second quarter and made up 45% of revenue, supporting a shift towards more specialised products. This mix helped lift the adjusted EBITDA margin to 26.0%. (Stevanato Group)
A customer won European regulatory approval for a therapy using Stevanato’s proprietary Alina pen injector and cartridge technology. This is evidence that its integrated drug-delivery products are reaching commercial use. (Stevanato Group)
Management expects lower GLP-1 syringe volumes from one customer to slow growth to low single digits in 2027. It says it has backfilled much, but not all, of the affected demand, leaving a near-term growth gap. (Investing.com)
Engineering revenue fell 12% in the third quarter, as weaker visual-inspection and assembly sales outweighed growth in after-sales services. The segment also faces uneven order conversion and project timing, making recovery less predictable. (Business Wire, Investing.com)
The expansion programme still requires substantial spending: third-quarter capital expenditure was €44.8m, and net debt stood at €353.7m at quarter-end. If new capacity takes longer to fill, those investments could weigh on cash generation and returns. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Stevanato Group News
AllArticlesVideos

STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law
Business Wire2 weeks ago

Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R.
Business Wire2 weeks ago

Lost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price Drop
Business Wire2 weeks ago
Funds containing Stevanato Group
Fund name | Fund size | $STVN weighting |
|---|---|---|
Invesco Dow Jones Islamic Global Developed Markets$IGDA | $1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.